Screener
Palvella Therapeutics PVLA EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
| Other comprehensive loss: | ||
| Unrealized gain on investments | 4 | — |
| Foreign currency translation gain (loss) | 8 | (6) |
| Comprehensive loss | $(15,755) | $(8,191) |
| Net loss per share of Common Stock – basic and diluted | $(1.20) | $(0.74) |
| Weighted-average shares used in computing net loss per share of Common Stock – basic and diluted | 13,085,271 | 11,013,697 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's EPS (basic)?
- Palvella Therapeutics (PVLA) reported EPS (basic) of -$1.20 in Q1 2026.
- How has Palvella Therapeutics's EPS (basic) changed year-over-year?
- Palvella Therapeutics's EPS (basic) decreased by 62.2% year-over-year, from -$0.74 to -$1.20.
- What is the long-term trend for Palvella Therapeutics's EPS (basic)?
- Over 2 years (2021 to 2025), Palvella Therapeutics's EPS (basic) has grown at a 131.9% compound annual growth rate (CAGR), from -$0.69 to -$3.71.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Palvella Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude